Desentum, a clinical-stage biotechnology company developing novel allergen immunotherapies, today announced that its Phase 2 clinical study evaluating DM‑101PX for the treatment of birch pollen allergy has completed enrolment. 97 participants have been randomised into the BASIT study which is conducted in Canada.
The BASIT study is a randomized, double-blind, placebo-controlled Phase 2 trial designed to demonstrate the clinical effect of a short‑course treatment on allergic symptoms induced by a nasal allergen challenge and to assess the persistence of this effect. DM-101PX is an investigational immunotherapy product intended to provide long-lasting relief from birch pollen allergy symptoms with a shorter treatment regimen compared to traditional allergen immunotherapy.
“We are very pleased to have completed enrolment in the BASIT study,” said Pekka Mattila, CEO of Desentum. “This marks an important milestone in the clinical development of DM-101PX and advances our mission to validate a technology platform that we believe can be applied to create faster and more effective treatments for multiple allergies.”
With all participants now enrolled, the study will continue through the treatment and post-treatment efficacy assessment periods. Topline results are expected in late 2026.
About DM-101PX
The active substance in DM-101PX is DM-101, a recombinant birch pollen allergen modified to reduce its allergenic potential. DM-101PX contains a formulation optimized to support the controlled release of DM-101 after subcutaneous injection.
About Desentum
Desentum Oy is a clinical-stage biopharmaceutical company based in Espoo, Finland, leveraging high-resolution protein engineering and novel formulations for designing allergy vaccines that enable short-course treatment to restore long-term tolerance. Desentum, founded in 2011, is a spin-off company from VTT Technical Research Centre of Finland Ltd. With its product development, Desentum targets both respiratory and food allergies.